X
AVDL

Xponance’s Avadel Pharmaceuticals AVDL Stock Holding History

Xponance’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,763
Closed -$210K – 1693
2025
Q4 		$210K Buy
+9,763
New +$190K ﹤0.01% 1368

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Xponance's AVDL Position: Q1 2026 in Review

Xponance sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 9,763 shares — an estimated $210K sold.

Xponance first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $210K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Xponance reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Xponance sold 9,763 Avadel Pharmaceuticals shares in Q1 2026, an estimated $210K.
  • Xponance first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Xponance's Avadel Pharmaceuticals position peaked at $210K in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.